Motility®, Misk Pharma’s first generic Prucalopride in the MENA region, introduces a targeted prokinetic approach to chronic idiopathic constipation.

A Targeted Approach to Colonic Motility

Unlike conventional laxatives, Prucalopride reactivates colonic motility at its source, delivering consistent bowel function, sustained symptom improvement, and enhanced patient quality of life.

This advanced treatment approach is supported by robust clinical evidence and a strong safety profile.

Motility® is proudly manufactured in Jordan under global GMP standards, reaffirming Misk Pharma’s leadership in advanced gastroenterology solutions.